Диссертация (Изучение высвобождения лекарственных веществ в биорелевантных средах), страница 16
Описание файла
Файл "Диссертация" внутри архива находится в папке "Изучение высвобождения лекарственных веществ в биорелевантных средах". PDF-файл из архива "Изучение высвобождения лекарственных веществ в биорелевантных средах", который расположен в категории "". Всё это находится в предмете "фармацевтика" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата фармацевтических наук.
Просмотр PDF-файла онлайн
Текст 16 страницы из PDF
– С. 22-26.13546.ходыкШохин И.Е., Раменская Г.В., Давыдова К.С.. Современные подвалидацииметодикиспытания«Растворение»//Химико-фармацевтический журнал. – Москва, 2011. – т. 45. – №3. – С. 92-95.47.Юргель Н.В. Анализ состояния фармацевтического рынка России// Ремедиум. 2009. №2.С.7.48.Aaltonen J.; Rades T. Commentary: Towards Physico-Relevant Disso-lution Testing: The Importance of Solid-State Analysis in Dissolution.
// Dissolution Technologies. – 2009. – № 16(2). – рр. 47-54.49.Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P.Investigation of preparation parameters to improve the dissolution of poorly watersoluble meloxicam. // Int J Pharm. 2009 Nov 3;381(2)50.Becker C., Dressman J., Amidon G. et al, Biowaiver Monographsfor Immediate Release Solid Oral Dosage Forms: Ethambutol Dihydrochloride //Journal of Pharmaceutical Sciences. – 2008. – Vol. 97.
– pp. 1350–1360.51.Boni J. E.; Brickl R. S.; Dressman J. B.; Pfefferle M. L. Instant FaS-SIF and FeSSIF—Biorelevance Meets Practicality. // Dissolution Technologies. –2009. – № 16(3). – рр. 41-46.52.British Pharmacopoeia 2009. British Pharmacopoeia CommissionSecretariat of the Medicines and Healthcare products Regulatory Agency. – London, United Kingdom, 2009.53.Burmicz J.. Technical Note: Why Is Vibration an Issue for DissolutionTesting? // Dissolution Technologies. – 2008. – Vol. 15, № 1.54.Cardot J-M., Beyssac E., Alric M. In vitro–In vivo Correlation: Im-portance of Dissolution in IVIVC // Dissolution Technologies.
– 2007. – Vol. 14,No 1.55.Chen M., Shah V., Patnaik R. Bioavailability and Bioequivalence: AnFDA Regulatory Overview // Pharmaceutical Research. – 2001. – Vol. 18, №. 12.56.Chuasuwan B., Binjesoh V., Polli J.E.. Biowaiver Monographs forImmediate Release Solid Oral Dosage Forms: Diclofenac Sodium and Diclofenac136Potassium / Journal of Pharmaceutical Sciences. – 2009. – Vol. 98. – pp.
1206–1219.57.Cook J., Bockbrader H. An Industrial Implementation of the Bio-pharmaceutics Classification System // Dissolution Technologies – 2002. – Vol. 9,№ 2.58.Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution test-ing as a prognostic tool for oral drug absorption: Immediate Release dosage forms// Pharmaceutical Research. – 1998. – Vol. 15, №1.59.Dressman, J. B., Amidon, G. L., Reppas, C., Shah, V.
P. Dissolution testingas a prognostic tool for oral drug absorption: immediate release dosage forms. // Pharm.Res. – 1998. – № 15 (1). – рр. 11–22.60.Dressman, J. B., Reppas C. In vitro–in vivo correlations for lipophilic, poorlywater-soluble drugs. // Eur. J. Pharm. Sci.
– 2000. – № 11 (Suppl 2). – рр. 73–80.61.Emami J. In vitro-in vivo correlation: From theory to applications// Journal of Pharmaceutical Sciences. – 2006. – Vol. 9. – pp. 169-189.62.European Pharmacopoeia, 7th ed. European Directorate for the Qualityof Medicines, Council of Europe. – Strasbourg, France, 2010.63.Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, BergströmCA. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevantdissolution media.
// Mol Pharm. 2010 Oct 4;7(5):1419-3064.Fang JB, Robertson VK, Rawat A, Flick T, Tang ZJ, Cauchon NS,McElvain JS. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development. // Mol Pharm. 2010Oct 4;7(5):1466-7765.Ferraz H.
G., Carpentieri L. N., Watanabe S. P. Dissolution Pro-file Evaluation of Solid Pharmaceutical Forms Containing Chloramphenicol Marketed in Brazil // Brazilian Archives of Biology and Technology. – 2007. – Vol.50,№. 1 – pp.57-65.66.Fliszar K., Forsyth R., Li Z., Martin G.. Effects of Dissolved Gases inSurfactant Dissolution Media // Dissolution Technologies. – 2005. – Vol. 12, No 3.13767.Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, DressmanJB. Evaluation of Various Dissolution Media for Predicting In Vivo Performanceof Class I and II Drugs. // Pharm. Res. – 1998,.
– № 15(5). – рр. 698-705.68.Garbacz G, Klein S, Weitschies W. A biorelevant dissolution stresstest device - background and experiences. // Expert Opin Drug Deliv. 2010Nov;7(11).69.Gianotto E. A., Arantes R. P., Lara-Filho M. J. et all. Dissolution testfor glibenclamide tablets // Quimica Nova. – 2007. – Vol. 30, No. 5. – рр. 1218–1221.70.Guidance for Industry Immediate Release Solid Oral Dosage FormsScale-Up and Post-approval Changes: Chemistry, Manufacturing, and Controls, Invitro Dissolution Testing, and In vivo Bioequivalence Documentation (FDA, 1995)71.Guidance for Industry: Analytical procedures and method validation(draft).
// U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). U.S. GovernmentPrinting Office: Washington, DC, 2000.72.Guidance for Industry: Waiver of In vivo Bioavailability and Bioe-quivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on aBiopharmaceutics Classification System / Food and Drug Administration.
Centerfor Drug Evaluation and Research (CDER). – FDA, 2000.73.Guidance on the Selection of Comparator Pharmaceutical Products forEquivalence Assessment of Interchangeable Multisource (Generic) Products /WHO Technical Report Series, №902. WHO, 2002.74.Hofer J., Gray V.. Examination of Selection of Immediate ReleaseDissolution Acceptance Criteria // Dissolution Technologies.
– 2003. – Vol. 10, No1.75.Hussain A., Lesko L., Lo et all K.. The Biopharmaceutics Classifica-tion System: Highlights of the FDA's Draft Guidance // Dissolution Technologies.– 1999. – Vol. 6, № 2.13876.ICH Harmonised Tripartite Guideline: The Common Technical Doc-ument for the Registration of Pharmaceuticals for Human Use: Quality M4Q (R1).– Geneva: ICH, 2002.77.ICH Harmonised Tripartite Guideline: The Common Technical Doc-ument for the Registration of Pharmaceuticals for Human Use: Safety. M4S (R2).– Geneva: ICH, 2002.78.ICH Harmonised Tripartite Guideline: The Common Technical Doc-ument for the Registration of Pharmaceuticals for Human Use: Efficacy. M4E(R1).
– Geneva: ICH, 2002.79.ICH Harmonized Tripartite Guidelines. ICH Q2A «Text on Validationof Analytical Procedures». – ICH, Geneva, 1995.80.ICH Harmonized Tripartite Guidelines. ICH Q2B «Validation of Ana-lytical Procedures: Methodology». – ICH, Geneva, 1997.81.Induri M, Mantripragada BR, Yejella RP, Kunda PR, NannapaneniDT, Boddu R. Dissolution studies and quantification of meloxicam in tablet dosageform by spectrophotometry. // Pak J Pharm Sci. 2012 Jan;25(1)82.Interchangeability of multisource drug products containing highly var-iable drugs. WHO/FIP Training Workshop on Dissolution, Pharmaceutical ProductInterchangeability and Biopharmaceuticals Classification System (BCS) - Kiev,2007.
2г83.International Pharmacopoeia, 4th ed. (incl. First and Second Supple-ments) – WHO, Geneva – 2011.84.Jantratid E., Prakongpan S., Dressman J.B. et al. Biowaiver Mono-graphs for Immediate Release Solid Oral Dosage Forms: Cimetidine // Journal ofPharmaceutical Sciences. – 2006. – Vol. 95. – pp. 974–984.85.Jantratid Е; Dressman J. B. Biorelevant Dissolution Media Simulating theProximal Human Gastrointestinal Tract: An Update. // Dissolution Technologies.
– 2009.– № 16(3). – рр. 21-25.13986.Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B. Dissolution media sim-ulating conditions in the proximal human gastrointestinal tract: an update. . // Pharm.Res. – 2008. – № 25 (7). – рр. 1663–1676.87.Japanese Pharmacopoeia 16th ed. The Ministry of Health, Labor andWelfare. – 2011.88.Jogia H.; Mehta T.; and Patel M. Evaluation of Dissolution Media Containing aNovel Synthetic Surfactant by In Vitro Testing of BCS Class II Drugs.
// Dissolution Technologies. – 2009. – № 16(3). – рр.14-19.89.Karalis V, Magklara E, Shah VP, Macheras P. From drug deliverysystems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence andbiowaivers. // Pharm Res. 2010 Sep;27(9):2018-2990.Kleberg K, Jacobsen J, Müllertz A. Characterising the behaviour ofpoorly water soluble drugs in the intestine: application of biorelevant media forsolubility, dissolution and transport studies. // J Pharm Pharmacol. 2010Nov;62(11):1656-68.91.Klein S. he use of biorelevant dissolution media to forecast the in vivoperformance of a drug.
// AAPS J. 2010 Sep;12(3):397-406.92.Klein S. Predicting Food Effects on Drug Release from Extended-Release Oral Dosage. Forms Containing a Narrow Therapeutic. // DissolutionTechnologies. – 2009. – № 16(3). – рр. 28-40.93.Kostewicz, E. S., Brauns, U., Becker, R., Dressman, J. B. Forecasting the oralabsorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. // Pharm. Res. – 2002,.
